ArticleEndocrine connections2025
Genome-wide insights of shared genetic architecture between menstrual traits and bone mineral density.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: While the phenotypic associations of menstrual traits, such as age at menarche (AAM) and age at natural menopause (ANM), with bone mineral density (BMD) have been well observed, the understanding of their shared genetic mechanisms is lacking. We aimed to systematically explore the underlying genetic basis connecting AAM and ANM with BMD. Methods: We performed a large-scale genome-wide cross-trait analysis by leveraging summary statistics from the hitherto largest genome-wide association studies conducted among the European population for AAM (n = 556,124), ANM (n = 201,323), and heel estimated BMD (eBMD, n = 426,824), a robust validated predictor of osteoporosis risk. Results: We identified significant genetic correlations for eBMD with both AAM (r g = -0.082, P = 1.83 × 10-8) and ANM (r g = 0.044, P = 0.007). Cross-trait meta-analysis yielded 203 AAM-eBMD shared loci, of which 3 were novel and 77 ANM-eBMD shared loci, of which two were novel. Gene-based analysis revealed 409 AAM-eBMD shared genes and 179 ANM-eBMD shared genes. Mendelian randomization demonstrated that genetically predicted later AAM (β = -0.054, 95% CI = -0.069 to -0.040, P = 6.08 × 10-14) and genetically predicted earlier ANM (β = 0.010, 95% CI = 0.004-0.017, P = 0.003) were significantly associated with decreased levels of eBMD. No evidence of reverse causality was found. Conclusion: Our work provides evidence in support of a substantial shared genetic basis and causal relationships between menstrual traits and BMD. The findings could be instrumental in developing risk stratification strategies and formulating novel pharmaceutical interventions for osteoporosis. Strengths and limitations of the study: Genome-wide cross-trait design provided insights into the shared genetic basis and biological mechanisms underlying the phenotypic associations between AAM, ANM, and eBMD. The adoption of the hitherto largest GWAS summary statistics ensured statistical power. The genetic data were exclusively from European ancestry, limiting the generalizability of our results. Current findings are primarily derived from bioinformatic analyses and interpreted based on existing, incomplete biological knowledge of the SNPs and genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.